<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have tested granulocyte/macrophage-colony-stimulating-factor (rhGM-CSF, fully glycosylated, Sandoz, Schering/Plough) in 40 patients with chemotherapy-induced <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>The drug enhanced leukocyte recovery in 5 different dose levels (2-32 micrograms/kg body weight) if given by continuous intravenous infusion or subcutaneously for 5 days </plain></SENT>
<SENT sid="2" pm="."><plain>Patients who received rhGM-CSF during <z:e sem="disease" ids="C1167779" disease_type="Disease or Syndrome" abbrv="">neutropenic infections</z:e> (n = 32) survived significantly better if they recovered leukocytes to at least 1.5 x 10(9)/l </plain></SENT>
<SENT sid="3" pm="."><plain>In patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and excess of blasts (n = 82) remission could be induced in nearly 50% if the drug was given together with low dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (LD-AraC) </plain></SENT>
<SENT sid="4" pm="."><plain>The results of these phase-II-studies show that rhGM-CSF is a safe drug which may save many patients from life-threatening situations during haematopoietic insufficiency </plain></SENT>
</text></document>